Astec Lifesciences Limited

BSE: 533138 NSE: ASTEC
Astec Lifesciences Limited - pharma in Mumbai, Maharashtra, India. FY 2026 financials & compliance.
CIN L99999MH1994PLC076236 Incorporated 25 January 1994 ROC Mumbai HQ Mumbai, Maharashtra, India
Active Listed - NSE: ASTEC · BSE: 533138 Public Limited Company pharma
Market Cap
₹1,197 Cr
ASTEC · NSE
Share Price
₹551.85
+2.77% today
Revenue
₹448 Cr
FY 2025-26 · +17.5% YoY
EBITDA
−₹6.62 Cr
Margin -1.5%
Net Profit
−₹78.76 Cr
FY 2025-26 · +42.4% YoY
ROE
-25.9%
ROCE -5.7%
Debt / Equity
1.60
Interest cover -67.0x
Authorised capital
₹25 Cr
Registered with MCA

About Astec Lifesciences Limited

Data last updated:

Astec Lifesciences Limited is a public limited company based in Mumbai, Maharashtra, India, a subsidiary of Godrej Agrovet Limited. It operates in the API manufacturers segment of the pharmaceuticals sector. It was incorporated on 25 January 1994 and has been in existence for over 32 years.

The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN L99999MH1994PLC076236. Its GSTIN is 27AAACA4832D1Z4 (Maharashtra). The company holds 6 GST registrations, of which 1 is active. It is a listed company as per MCA records. Its shares are listed on BSE: 533138 and NSE: ASTEC.

The company has an authorised share capital of ₹25 Cr and a paid-up capital of ₹22.28 Cr. It was formerly known as Urshila Traders Private Limited. It is led by directors including Ashok Vishwanath Hiremath and Rishinaradamangalam Govindan.

Its last annual general meeting (AGM) was held on 31 July 2026, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Godrej One 3rd Floor Pirojshanagar Eastern Express Highway Vikhroli (East), Mumbai, Maharashtra, India – 400079.

As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹448.15 Cr, a growth of 17.5% compared to the previous year. For the same year it recorded a net loss of ₹78.76 Cr (net margin -17.6%) and EBITDA of -₹6.62 Cr (EBITDA margin -1.5%). The net worth stands at ₹390.6 Cr (up 66.4% YoY). Total assets are valued at ₹841.14 Cr (up 6.4% YoY).

The company has about 615 employees on its provident fund (EPFO) records. Its group structure includes 1 subsidiary.

The company is associated with 1 brand: Astec LifeSciences. As per MCA filings, the company has satisfied charges of ₹467.94 Cr on record. Court records list 48 cases involving the company, including 30 filed by the company and 18 filed against it; 8 cases are pending. The company has 98 deals on record (96 market trades, 1 ipo, 1 acquisition); the latest was in September 2026. The company has 2 MSME Form 1 returns on record for the period ending Sep 2019, listing 77 overdue payments to 23 micro and small suppliers.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website astecls.com.

Company details

CIN L99999MH1994PLC076236
Registration Number 076236
Incorporation Date 25 January 1994
ROC Mumbai
Listing Status Listed - Listed on NSE (ASTEC); Listed on BSE (533138)
Company Status Active
Parent Company Godrej Agrovet Limited
Compliance Status Active Compliant

CIN history

Astec Lifesciences has one previous CIN (Corporate Identification Number): U99999MH1994PLC076236. The current CIN is L99999MH1994PLC076236, which is the unique identifier assigned by the Registrar of Companies.

CINStatus
L99999MH1994PLC076236Current
U99999MH1994PLC076236Previous
Key People
Ashok Vishwanath Hiremath Director Rishinaradamangalam Govindan Director Nandkumar Vasant Dhekne Director

Contact details

Astec Lifesciences Limited's registered office is in Mumbai, Maharashtra. Its website is astecls.com. Its e-mail address and telephone number are in the company report.

  • Email
  • Telephone
  • Website
    astecls.com
  • Social Media
  • Registered Address
    Godrej One 3rd Floor Pirojshanagar Eastern Express Highway Vikhroli (East), Mumbai, Maharashtra, India – 400079
  • Industry
    Pharma, API Manufacturers

To see the full contact details of Astec Lifesciences Limited, buy the company report.

Comprehensive company report
Astec Lifesciences Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Brands

Astec Lifesciences operates one associated brand: Astec LifeSciences. Each brand links to its own profile.

BrandDescriptionWebsite
Astec LifeSciences
Organic intermediates are manufactured for pharmaceutical and agrochemical sectors.astecls.com

Business activity

The main business activity of Astec Lifesciences is manufacturing. In detail, this covers manufacture of chemicals and chemical products.

Main activity group codeMain activityBusiness activity codeBusiness activityShare of turnover
CManufacturing20Manufacture of chemicals and chemical products

To see the full business activity and turnover split of Astec Lifesciences Limited, buy the company report.

Financials of Astec Lifesciences Limited

FY 2025-26 filings available

Astec Lifesciences Limited reported revenue of ₹448.15 Cr (up 17.5% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹448 Cr
+17.5% YoY
EBITDA
−₹6.62 Cr
+90.0% YoY
Profit After Tax
−₹78.76 Cr
+42.4% YoY
Net Worth
₹391 Cr
+66.4% YoY
Total Assets
₹841 Cr
+6.4% YoY
Total Debt
₹449 Cr
-19.0% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue448381458628677555523
Revenue growth+17.5%-16.8%-27.1%-7.2%+21.9%+6.2%-
EBITDA(6.62)(66.22)(5.91)76.2615411285.17
EBITDA margin-1.5%-17.4%-1.3%+12.1%+22.8%+20.1%+16.3%
Profit before tax(81.00)(141)(61.75)34.9612189.0761.35
Net profit(78.76)(137)(46.83)25.9589.8665.0647.64
Net profit margin-17.6%-35.9%-10.2%+4.1%+13.3%+11.7%+9.1%
EPS (₹)(36.31)(68.71)(23.93)13.0445.8533.2124.28
Balance sheet
Total assets841790866763677497346
Net worth391235369419396309247
Total debt44955549434127918798.71
Cash & bank12.252.712.432.162.131.571.49
Net working capital342250296303304155112
Cash flow
Cash from operations(80.71)(8.40)10.2274.6623.60(8.16)168
Cash from investing(4.31)(15.23)(135)(113)(104)(73.14)(73.81)
Cash from financing94.4923.7312537.7780.4881.34(94.53)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue72.0283.5615912573.7291.0812093.86
Revenue growth (YoY)-2.3%-8.3%+32.7%+32.9%-25.2%+31.3%--
Other income0.620.732.630.821.120.510.791.91
EBITDA(19.79)(0.67)9.161.89(6.69)(10.99)5.53(5.74)
EBITDA margin-27.5%-0.8%+5.8%+1.5%-9.1%-12.1%+4.6%-6.1%
Depreciation11.1811.0711.7711.2210.4411.4911.5811.40
Interest7.077.737.927.178.4011.0410.409.92
Profit before tax(37.42)(18.74)(7.90)(15.68)(24.41)(33.01)(15.66)(25.15)
Tax(0.03)(0.03)(0.15)0.010.010.010.4115.22
Net profit(37.39)(18.71)(7.75)(15.69)(24.42)(33.02)(16.07)(40.37)
EPS (₹)(16.79)(8.40)(3.48)(7.04)(11.35)(16.85)(8.20)(20.59)
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue448381458628677555522
Revenue growth+17.5%-16.8%-27.1%-7.2%+21.9%+6.3%-
EBITDA(6.60)(66.21)(5.91)76.2715411285.20
EBITDA margin-1.5%-17.4%-1.3%+12.1%+22.8%+20.1%+16.3%
Profit before tax(81.17)(141)(61.88)34.8612188.6761.27
Net profit(78.85)(137)(46.88)25.9189.8164.7447.59
Net profit margin-17.6%-35.9%-10.2%+4.1%+13.3%+11.7%+9.1%
EPS (₹)(36.36)(68.74)(23.96)13.0245.8333.0324.26
Balance sheet
Total assets840789865762677497346
Net worth390234369419396309246
Total debt44955549434128018899.07
Cash & bank10.971.501.391.381.811.561.45
Net working capital341249295302304155112
Cash flow
Cash from operations(80.59)(8.39)10.1374.3223.41(8.06)169
Cash from investing(4.32)(15.13)(135)(112)(104)(73.11)(73.81)
Cash from financing94.3823.6212537.6680.3781.23(94.64)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue72.0283.5615912573.7291.0812093.86
Revenue growth (YoY)-2.3%-8.3%+32.7%+32.9%-25.2%+31.3%--
Other income0.600.712.610.791.090.490.781.89
Total expenses91.8184.2314912380.4010211499.60
EBITDA(19.79)(0.67)9.161.90(6.68)(10.99)5.53(5.74)
EBITDA margin-27.5%-0.8%+5.8%+1.5%-9.1%-12.1%+4.6%-6.1%
Depreciation11.2011.0911.7911.2410.4611.5111.5911.42
Interest7.087.747.937.188.4111.0510.409.92
Profit before tax(37.47)(18.79)(7.95)(15.73)(24.46)(33.06)(15.68)(25.19)
Tax(0.04)(0.04)(0.16)0.000.000.000.4115.22

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 15 Nov 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue72.0283.5615912573.7291.0812093.86
Revenue growth (YoY)-2.3%-8.3%+32.7%+32.9%-25.2%+31.3%--
Other income0.620.732.630.821.120.510.791.91
EBITDA(19.79)(0.67)9.161.89(6.69)(10.99)5.53(5.74)
EBITDA margin-27.5%-0.8%+5.8%+1.5%-9.1%-12.1%+4.6%-6.1%
Depreciation11.1811.0711.7711.2210.4411.4911.5811.40
Interest7.077.737.927.178.4011.0410.409.92
Profit before tax(37.42)(18.74)(7.90)(15.68)(24.41)(33.01)(15.66)(25.15)
Tax(0.03)(0.03)(0.15)0.010.010.010.4115.22
Net profit(37.39)(18.71)(7.75)(15.69)(24.42)(33.02)(16.07)(40.37)
EPS (₹)(16.79)(8.40)(3.48)(7.04)(11.35)(16.85)(8.20)(20.59)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue448381458628677555523
Revenue growth+17.5%-16.8%-27.1%-7.2%+21.9%+6.2%-
Other income5.075.635.6413.0610.477.9211.93
Total expenses455448464552522443437
Employee cost62.9161.1061.7452.2650.3138.3529.92
EBITDA(6.62)(66.22)(5.91)76.2615411285.17
EBITDA margin-1.5%-17.4%-1.3%+12.1%+22.8%+20.1%+16.3%
Depreciation44.9243.7136.2533.6534.3625.6623.16
Interest34.5336.7025.2320.719.064.7512.59
Profit before tax(81.00)(141)(61.75)34.9612189.0761.35
Tax(0.12)(6.28)(14.85)9.3631.2424.0013.82
Net profit(78.76)(137)(46.83)25.9589.8665.0647.64
Net profit margin-17.6%-35.9%-10.2%+4.1%+13.3%+11.7%+9.1%
EPS (₹)(36.31)(68.71)(23.93)13.0445.8533.2124.28
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital22.2819.6119.6119.6119.6019.5919.57
Reserves & surplus368215350400377290227
Shareholders' funds (net worth)391235369419396309247
Minority interest0.310.270.230.190.160.140.33
Secured loans0.000.0011.9445.0459.1918.1723.89
Unsecured loans44955548229622016974.82
Total debt44955549434127918798.71
Total liabilities841790866763677497346
Assets
Gross block754749592488477316271
Net block459499386318340213194
Capital work in progress19.6021.3716512722.8211624.11
Investments0.010.010.010.010.010.010.01
Inventories138160196295187106121
Sundry debtors248147169155274187161
Cash & bank balances12.252.712.432.162.131.571.49
Loans & advances44.9931.1831.2146.9552.9735.6148.25
Total current assets443341398499516330332
Total current liabilities10191.17102196211175220
Net working capital342250296303304155112
Total assets841790866763677497346
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash0.580.470.470.550.340.310.21
Net cash from operating activities(80.71)(8.40)10.2274.6623.60(8.16)168
Net cash from investing activities(4.31)(15.23)(135)(113)(104)(73.14)(73.81)
Net cash from financing activities94.4923.7312537.7780.4881.34(94.53)
Net change in cash9.470.100.00(0.08)0.220.030.10
Closing cash12.252.712.432.162.131.571.49
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+17.5%-16.8%-27.1%-7.2%+21.9%+6.2%-
EBITDA growth+90.0%-1020.5%-107.8%-50.5%+38.1%+31.0%-
PBT growth+42.6%-128.3%--71.1%+36.0%+45.2%+9.8%
Net income growth+42.4%-192.1%-280.5%-71.1%+38.1%+36.6%-
Revenue CAGR (3Y)-10.7%-17.4%-6.2%+6.3%+16.2%+14.7%+20.5%
EBITDA CAGR (3Y)----3.6%+26.3%+27.7%+18.0%
Profitability & leverage
Net income margin-18.1%-35.3%-10.2%+4.1%+13.3%+11.7%+9.1%
Return on capital employed-5.7%-12.6%-4.5%+7.7%+22.2%+22.3%+20.4%
Return on net worth-25.9%-44.6%-11.9%+6.3%+25.5%+23.4%+21.2%
Debt / equity1.601.741.060.760.660.510.61
Long-term debt / equity0.470.650.200.010.060.070.00
Interest cover-67.00-33.38-59.8448.607.575.5320.30
Efficiency & per share
Fixed asset turnover0.600.570.851.301.711.892.12
Inventory turnover3.012.141.872.614.624.884.88
Debtors turnover2.272.412.832.932.943.193.70
EPS (₹)(36.31)(68.71)(23.93)13.0445.8533.2124.28
Dividend per share (₹)0.000.000.001.501.501.501.50
Book value per share (₹)175.30119.70188.32213.90202.32157.84126.00
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue72.0283.5615912573.7291.0812093.86
Revenue growth (YoY)-2.3%-8.3%+32.7%+32.9%-25.2%+31.3%--
Other income0.600.712.610.791.090.490.781.89
Total expenses91.8184.2314912380.4010211499.60
EBITDA(19.79)(0.67)9.161.90(6.68)(10.99)5.53(5.74)
EBITDA margin-27.5%-0.8%+5.8%+1.5%-9.1%-12.1%+4.6%-6.1%
Depreciation11.2011.0911.7911.2410.4611.5111.5911.42
Interest7.087.747.937.188.4111.0510.409.92
Profit before tax(37.47)(18.79)(7.95)(15.73)(24.46)(33.06)(15.68)(25.19)
Tax(0.04)(0.04)(0.16)0.000.000.000.4115.22
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue448381458628677555522
Revenue growth+17.5%-16.8%-27.1%-7.2%+21.9%+6.3%-
Other income4.995.565.5813.0410.467.6711.93
Total expenses455448464552522443437
Employee cost62.9161.1061.7452.2650.3138.3529.92
EBITDA(6.60)(66.21)(5.91)76.2715411285.20
EBITDA margin-1.5%-17.4%-1.3%+12.1%+22.8%+20.1%+16.3%
Depreciation44.9943.7736.3133.7134.4225.7123.22
Interest34.5736.7125.2420.749.094.7912.64
Profit before tax(81.17)(141)(61.88)34.8612188.6761.27
Tax(0.16)(6.31)(14.89)9.3331.2223.9813.81
Net profit(78.85)(137)(46.88)25.9189.8164.7447.59
Net profit margin-17.6%-35.9%-10.2%+4.1%+13.3%+11.7%+9.1%
EPS (₹)(36.36)(68.74)(23.96)13.0245.8333.0324.26
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital22.2819.6119.6119.6119.6019.5919.57
Reserves & surplus368214349399376289227
Shareholders' funds (net worth)390234369419396309246
Secured loans0.000.000.000.0019.1918.0023.89
Unsecured loans44955549434126017075.18
Total debt44955549434128018899.07
Total liabilities840789865762677497346
Assets
Gross block755749592488477316271
Net block459499386318340213194
Capital work in progress19.6021.3716512722.8211624.11
Investments0.430.430.430.430.430.430.49
Inventories138160196295187106121
Sundry debtors248147169155274187161
Cash & bank balances10.971.501.391.381.811.561.45
Loans & advances44.9431.2131.2346.9752.9935.6248.23
Total current assets442340397498515330332
Total current liabilities10191.13102196212176220
Net working capital341249295302304155112
Total assets840789865762677497346
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash0.570.460.460.540.330.270.16
Net cash from operating activities(80.59)(8.39)10.1374.3223.41(8.06)169
Net cash from investing activities(4.32)(15.13)(135)(112)(104)(73.11)(73.81)
Net cash from financing activities94.3823.6212537.6680.3781.23(94.64)
Net change in cash9.470.100.00(0.09)0.220.060.11
Closing cash10.971.501.391.381.811.561.45
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+17.5%-16.8%-27.1%-7.2%+21.9%+6.3%-
EBITDA growth+90.0%-1020.3%-107.8%-50.5%+38.2%+30.9%-
PBT growth+42.5%-128.1%--71.2%+36.5%+44.7%+9.8%
Net income growth+42.4%-191.9%-280.9%-71.2%+38.7%+36.0%-
Revenue CAGR (3Y)-10.7%-17.4%-6.2%+6.4%+16.2%+14.7%+20.6%
EBITDA CAGR (3Y)----3.6%+26.3%+27.7%+18.1%
Profitability & leverage
Net income margin-18.1%-35.4%-10.3%+4.1%+13.3%+11.7%+9.1%
Return on capital employed-5.7%-12.6%-4.5%+7.7%+22.2%+22.2%+20.4%
Return on net worth-26.0%-44.7%-11.9%+6.3%+25.5%+23.3%+21.2%
Debt / equity1.611.741.060.760.660.520.61
Long-term debt / equity0.470.650.200.010.060.070.00
Interest cover-67.01-33.38-59.7848.737.605.5820.39
Efficiency & per share
Fixed asset turnover0.600.570.851.301.711.892.12
Inventory turnover3.012.141.872.614.624.884.88
Debtors turnover2.272.412.832.932.943.193.70
EPS (₹)(36.36)(68.74)(23.96)13.0245.8333.0324.26
Dividend per share (₹)0.000.000.001.501.501.501.50
Book value per share (₹)174.97119.36188.01213.61202.06157.60125.94

To see the full year-wise statements and ratios of Astec Lifesciences Limited, buy the company report.

Board of directors of Astec Lifesciences Limited

Astec Lifesciences has 10 current directors and 25 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Ashok Vishwanath Hiremath
Also directs: Cabernet Trading and Advisors LLP, Dai-Ichi Karkaria Limited, Envixera Solutions Private Limited and 5 more
Director25 Jan 199432 Years 9 MonthsCurrent
Rishinaradamangalam GovindanDirector30 Jan 20206 Years 9 MonthsCurrent
Nandkumar Vasant Dhekne
Also directs: John Cockerill India Limited, Elantas Beck India Limited, Ecochemie Private Limited and 2 more
Director18 Dec 20205 Years 10 MonthsCurrent
Anjali Rajesh Gupte
Also directs: John Cockerill India Limited, Godrej Foods Limited, Creamline Dairy Products Ltd.
Director18 Dec 20205 Years 10 MonthsCurrent
Burjis Nadir Godrej
Also directs: Godrej Industries Limited, Godrej Agrovet Limited, NRG Enterprise LLP and 2 more
Director25 Jul 20224 Years 3 MonthsCurrent
Sunil Kataria
Also directs: Godrej Foods Limited, Creamline Dairy Products Ltd., Behram Chemicals Pvt Ltd and 5 more
Director01 Sep 20251 Years 2 MonthsCurrent
Showing 6 of 10 current directors. View all directors

Auditor

Astec Lifesciences Limited is audited by B S R & Co. LLP for the financial year 2025.

Auditor firmFinancial yearFirm registration number
B S R & Co. LLPFY 2025101248W/W-100022

Shareholding

Shareholding for the quarter ended Sep 2026: promoters hold 72.00%, foreign institutional investors hold 0.00%, domestic institutional investors hold 3.30% and retail and other public shareholders hold 24.70%.

Promoters: 72.00%DII (Domestic Institutional): 3.30%Retail & Others: 24.70%
Sep 2026
QUARTER
72.00% Promoters
3.30% DII (Domestic Institutional)
24.70% Retail & Others
Promoter holding - history
Now 72.00% · Sep 2026High 72.40% · Dec 2025Low 72.00% · Mar 2026
71%71.8%72.5%73.3%74%Dec 2025Mar 2026Jun 2026Sep 2026Dec 2025: 72.40%Mar 2026: 72.00%Jun 2026: 72.00%Sep 2026: 72.00%72.40%72.00%72.00%
Shareholding trend - last 6 quarters
Sep 2026Jun 2026Mar 2026Dec 2025
Promoters72.00%72.00%72.00%72.40%
Public28.00%28.00%28.00%27.60%

Charges & borrowings

Open charges
None
Satisfied charges
₹467.94 Cr
Breakdown by lending institutions
Axis Bank Limited₹207.30 Cr
Idbi Bank Limited₹77.90 Cr
Others₹64.00 Cr
Icici Bank Limited₹46.50 Cr
The Shamrao Vithal Co-Op. Bank Ltd.₹26.80 Cr
Others₹45.44 Cr
Latest charge details
DateCharge IDLenderAmountStatusModified or satisfied on
20 Apr 201510570045Ifci Limited₹15 CrSatisfied
12 Nov 201410531301Others₹64 CrSatisfied
13 Aug 201410519630Icici Bank Limited₹6.5 CrSatisfied
13 Aug 201410519633Icici Bank Limited₹40 CrSatisfied
11 Aug 201310444906Idbi Bank Limited₹10 CrSatisfied

To see the full charge records of Astec Lifesciences Limited, buy the company report.

Total charge records: 31 View all charges

Deals & funding

Astec Lifesciences Limited has 98 deals on record (96 market trades, 1 ipo, 1 acquisition); the latest was in September 2026.

Total deals
98
Market trades
96
IPO
1
Acquisition
1

Deals on record (5 of 98)

WhenDealAmountParties
Sep 2026Market trade₹74.98 CrBuyer: Microcurves Trading Private Limited , Junomoneta Finsol Private Limited , Alphagrep Securities Private Limited
Seller: Microcurves Trading Private Limited , Junomoneta Finsol Private Limited , Alphagrep Securities Private Limited
May 2026Market trade₹9.29 CrBuyer: NK Securities Research Private Limited
Seller: NK Securities Research Private Limited
Apr 2026Market trade₹20.54 CrBuyer: NK Securities Research Private Limited , Mansi Share and Stock Broking Private Limited
Seller: NK Securities Research Private Limited , Mansi Share and Stock Broking Private Limited
Mar 2026Market trade₹13.22 CrBuyer: NK Securities Research Private Limited
Seller: NK Securities Research Private Limited
Dec 2025Market trade₹20.43 CrBuyer: Hrti Private Limited , Mathisys Quantcap LLP
Seller: Hrti Private Limited , Mathisys Quantcap LLP

To see the full deal history of Astec Lifesciences Limited, buy the company report.

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

Credit ratings & regulatory alerts

Astec Lifesciences Limited was last rated by Icra on 07 Apr 2022.

Rating agencyRated onRating
Icra07 Apr 2022

To see the full credit ratings and regulatory alerts of Astec Lifesciences Limited, buy the company report.

MSME payment delays

Astec Lifesciences Limited has 2 MSME Form 1 returns on record for the period ending Sep 2019, listing 77 overdue payments to 23 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.

Suppliers with reported dues (5 of 23)

SupplierAmount dueDue sinceReported on
Acid Industries
an individual supplier
Boisur Chemicals Private Limited
an individual supplier
an individual supplier

To see the full MSME payment records of Astec Lifesciences Limited, buy the company report.

Individuals and sole proprietors among the suppliers are not named.

Group structure & subsidiaries

Astec Lifesciences has 1 subsidiary company. This group structure data is as of FY 2025. The table lists each entity with its relationship and holding.

1
Subsidiary companies
Key subsidiaries
Company NameCINShares held
Behram Chemicals Pvt LtdU24100MH1993PTC071480

To see the full group structure of Astec Lifesciences Limited, buy the company report.

GST

Astec Lifesciences has 6 GST registrations: 1 active and 5 cancelled or inactive.

Total GSTINs
6
Active
1
Cancelled / inactive
5
GSTINStateStatusRegistered on
27AAACA4832D1Z4MaharashtraActive01 Jul 2017

To see the full GST registrations and return filing status of Astec Lifesciences Limited, buy the company report.

Recent activity

Astec Lifesciences Limited has 51 board changes on record since 1994: 30 appointments and 21 cessations. The latest: Arijit Mukherjee was appointed as Director on 04 Jul 2026.

AGM
Astec Lifesciences Limited last Annual general meeting of members was held on 31 Jul 2026 as per latest MCA records.
Appointed
Arijit Mukherjee was appointed as Director.
Appointed
Mathew Eipe was appointed as Director.
Appointed
Vishal Sharma was appointed as Director.
Filing
Astec Lifesciences Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Mumbai I.
Appointed
Sunil Kataria was appointed as Director.
Ceased
Balram Singh Yadav ceased to be Director.
Charges
A charge registered on 18 Jul 2013 via Charge ID 10441804 with Idbi Bank Limited was fully satisfied on 17 Dec 2024.
Charges
A charge registered on 10 Jan 2011 via Charge ID 10265432 with Idbi Bank Limited was fully satisfied on 17 Dec 2024.
Charges
A charge registered on 30 Jun 2009 via Charge ID 10172696 with Idbi Bank Limited was fully satisfied on 17 Dec 2024.
Ceased
Anurag Roy ceased to be Whole-Time Director.
Ceased
Brahma Nand Vyas ceased to be Director.

111 earlier events are in the company report.

News

ASTEC: Q2 REVENUE 720M RUPEES VS 737.2M (YOY)
26 Oct 2026 · Exchange Update
ASTEC: Q2 CONS NET LOSS 374M RUPEES VS LOSS 244.2M (YOY)
26 Oct 2026 · Exchange Update

Frequently asked questions

Astec Lifesciences is an active public limited company based in Mumbai, Maharashtra, India. The company works in api manufacturers, within the pharma industry. It was incorporated on 25 January 1994 (32+ years old) and is registered under CIN L99999MH1994PLC076236. Listed on BSE: 533138 and NSE: ASTEC.

Astec Lifesciences reported revenue of ₹448.15 Cr for FY 2025-26 (up 17.5% YoY) based on consolidated financials.

Astec Lifesciences has 10 current directors:

The latest financial statements of Astec Lifesciences on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 31 July 2026. Year-wise statements from 2015 are in the company report.

The GSTIN of Astec Lifesciences is 27AAACA4832D1Z4, registered in Maharashtra. The company has 6 GST registrations in all, of which 1 is active and 5 are cancelled or inactive.

The CIN (Corporate Identification Number) of Astec Lifesciences is L99999MH1994PLC076236. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Yes. Astec Lifesciences is a listed company as per MCA records. Its shares are listed on both BSE (code: 533138) and NSE (symbol: ASTEC).

Astec Lifesciences has 48 court cases on record: 30 filed by the company and 18 filed against it. 8 are pending. Most are in the district courts.

Astec Lifesciences was incorporated on 25 January 1994, making it 32+ years old. It is registered with the Registrar of Companies, Mumbai.

Astec Lifesciences has 98 deals on record (96 market trades, 1 ipo, 1 acquisition); the latest was in September 2026.

Arijit Mukherjee was appointed as Director on 04 Jul 2026. Mathew Eipe was appointed as Director on 13 Apr 2026. Vishal Sharma was appointed as Director on 13 Apr 2026. Astec Lifesciences has 51 board changes on record in total.